Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In Process Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Neurocrine Biosciences (NBIX) Long-Term Debt Repayments (2020 - 2022)

Neurocrine Biosciences filings provide 3 years of Long-Term Debt Repayments readings, the most recent being $279.0 million for Q2 2022.

On a quarterly basis, Long-Term Debt Repayments changed N/A to $279.0 million in Q2 2022 year-over-year; TTM through Sep 2023 was $279.0 million, a 0.0% change, with the full-year FY2024 number at $308.8 million, changed N/A from a year prior.
Long-Term Debt Repayments hit $279.0 million in Q2 2022 for Neurocrine Biosciences, up from $100000.0 in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $279.0 million in Q2 2022 to a low of $100000.0 in Q1 2021.
Median Long-Term Debt Repayments over the past 3 years was $186.9 million (2020), compared with a mean of $155.3 million.